FDA 483 - Emergent BioSolutions Canada Inc. - June 12, 2026

An FDA inspection of Cangene Corporation in Winnipeg, Canada, revealed ten significant observations related to manufacturing controls, quality systems, and document management. Key issues included inadequate investigations into process interruptions, insufficient defect rate management, uncontrolled document usage, and deviations from written procedures, indicating a need for improved quality oversight.